For the year ending 2025-12-31, CRBU made $11,159K in revenue. -$148,277K in net income. Net profit margin of -1328.77%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Licensing and collaboration revenue (including 2,487 and 4,110 for years ended december31, 2025, and december31, 2024, respectively, from related parties) | 11,159 | 9,994 | ||
| Research and development | 109,439 | 130,153 | ||
| General and administrative | 37,914 | 46,457 | ||
| Impairment charges | 12,150 | - | ||
| Total operating expenses | 159,503 | 176,610 | ||
| Loss from operations | -148,344 | -166,616 | ||
| Impairment of equity method investment | -9,158 | - | ||
| Other income, net | 8,827 | 15,348 | ||
| Change in fair value of the mskcc success payments liability | - | -2,154 | ||
| Total other (expense) income | -331 | 17,502 | ||
| Net loss before benefit from income taxes | -148,675 | -149,114 | ||
| Benefit from income taxes | -550 | -9 | ||
| Net loss | -148,125 | -149,105 | ||
| Net unrealized (loss) gain on available-for-sale marketable securities, net of tax | -152 | 225 | ||
| Net comprehensive loss | -148,277 | -148,880 | ||
| Basic EPS | -1.59 | -1.65 | ||
| Diluted EPS | -1.59 | -1.65 | ||
| Basic Average Shares | 93,389,283 | 90,317,925 | ||
| Diluted Average Shares | 93,389,283 | 90,317,925 | ||
Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)